AstraZeneca (LON:AZN) Reaches New 12-Month High – Should You Buy?

Shares of AstraZeneca PLC (LON:AZN) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as £154.74 and last traded at £135.85, with a volume of 422522813 shares trading hands. The stock had previously closed at £135.48.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AZN. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a £140 price objective on shares of AstraZeneca in a research note on Thursday, December 4th. Shore Capital reaffirmed a “buy” rating and set a £145 price target on shares of AstraZeneca in a research report on Thursday, November 6th. Berenberg Bank lifted their price objective on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday, October 21st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of £138.

AstraZeneca Stock Performance

The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The firm has a market capitalization of £211.95 billion, a P/E ratio of 22.71, a P/E/G ratio of 0.86 and a beta of 0.17. The stock has a fifty day moving average of £132.20 and a 200-day moving average of £119.15.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.